
Psychedelics in Behavioral Health: An Evolving Policy Conversation at a Pivotal Moment
Treatment-resistant depression is one of the most pressing challenges in behavioral health care. Up to 70 percent of people with major depression do not achieve remission with first-line medications, and roughly 30 percent develop treatment-resistant depression. Treatment-resistant depression is associated with higher mortality and suicide risk, as well as greater health care costs. Because depressive episodes can last nearly three times longer than in well-managed cases, the condition is linked to increased emergency department use, psychiatric hospitalization, homelessness, substance misuse, and long-term disability.


























